Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7,865 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A randomized, open-label, single-dose, two-cycle crossover study to evaluate the bioequivalence and safety of lenvatinib and Lenvima® in Chinese healthy subjects.
Xu Z, Wang Y, Liu G, Chen J, Wang W, Cheng Y, Ren Q, Cui Y, Yang W, Liu Z, Chen X, Xue J, Chang T, Qu X, Yu S, Zhou Y, Xu K, Su Z, Deng Q, Zhao Y, Yang H. Xu Z, et al. Among authors: su z. Expert Opin Investig Drugs. 2022 Jul;31(7):737-746. doi: 10.1080/13543784.2022.2067528. Epub 2022 Apr 19. Expert Opin Investig Drugs. 2022. PMID: 35427205 Clinical Trial.
A randomized, crossover, phase I clinical study to evaluate bioequivalence and safety of tofacitinib and Xeljanz® in Chinese healthy subjects.
Xu Z, Wang Y, Liu Z, Zhang R, Zhou Y, Yu J, Lan J, Liang W, Liu G, Qu X, Chen J, Su Z, Yu S, Cheng Y, Wang W, Ren Q, Deng Q, Zhao Y, Yang H. Xu Z, et al. Among authors: su z. Int Immunopharmacol. 2022 Aug;109:108780. doi: 10.1016/j.intimp.2022.108780. Epub 2022 Apr 20. Int Immunopharmacol. 2022. PMID: 35461158 Clinical Trial.
A randomized, open-label, two-cycle, two-crossover phase I clinical trial comparing the bioequivalence and safety of afatinib and Giotrif® in healthy Chinese subjects.
Liu G, Xue J, Wang Y, Liu Z, Li X, Qu D, Su Z, Xu K, Qu X, Qu Z, Sun L, Cao M, Wang Y, Chen X, Yu J, Liu L, Deng Q, Zhao Y, Zhang L, Yang H. Liu G, et al. Among authors: su z. J Cancer Res Clin Oncol. 2023 Jun;149(6):2585-2593. doi: 10.1007/s00432-022-04148-1. Epub 2022 Jun 30. J Cancer Res Clin Oncol. 2023. PMID: 35771264 Clinical Trial.
A randomized, double-blind, single-dose, parallel phase I clinical trial to compare the bioequivalence, immunogenicity, and safety of bevacizumab biosimilar and bevacizumab in healthy Chinese subjects.
Liu Z, Gao Z, Yang W, Zhang L, Xiao N, Qu D, Su Z, Xu K, Liu G, Wang Y, Ren Q, Yu S, Cheng Y, Zhou Y, Deng Q, Zhao Y, Wang Z, Yang H. Liu Z, et al. Among authors: su z. Expert Opin Drug Metab Toxicol. 2022 Jul-Aug;18(7-8):519-527. doi: 10.1080/17425255.2022.2113382. Epub 2022 Aug 18. Expert Opin Drug Metab Toxicol. 2022. PMID: 35961948 Clinical Trial.
Pharmacokinetics and safety of dasatinib and its generic: a phase I bioequivalence study in healthy Chinese subjects.
Wang Y, Xue J, Su Z, Cui Y, Liu G, Yang W, Liu Z, Chen J, Ren Q, Yu S, Cheng Y, Zhou Y, Wang W, Chen X, Qu D, Deng Q, Zhao Y, Yang H. Wang Y, et al. Among authors: su z. Expert Opin Investig Drugs. 2023 Mar;32(3):263-270. doi: 10.1080/13543784.2023.2179481. Epub 2023 Feb 18. Expert Opin Investig Drugs. 2023. PMID: 36757390 Clinical Trial.
Circadian tumor infiltration and function of CD8+ T cells dictate immunotherapy efficacy.
Wang C, Zeng Q, Gül ZM, Wang S, Pick R, Cheng P, Bill R, Wu Y, Naulaerts S, Barnoud C, Hsueh PC, Moller SH, Cenerenti M, Sun M, Su Z, Jemelin S, Petrenko V, Dibner C, Hugues S, Jandus C, Li Z, Michielin O, Ho PC, Garg AD, Simonetta F, Pittet MJ, Scheiermann C. Wang C, et al. Among authors: su z. Cell. 2024 May 2:S0092-8674(24)00410-0. doi: 10.1016/j.cell.2024.04.015. Online ahead of print. Cell. 2024. PMID: 38723627
7,865 results